Contribution of locus coeruleus-derived galanin to opioid reward and reinforcement

蓝斑源甘丙肽对阿片类药物奖励和强化的贡献

基本信息

  • 批准号:
    10669138
  • 负责人:
  • 金额:
    $ 46.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-30 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary The opioid epidemic has been declared a national public health emergency. Current treatments have abuse liability, target acute overdose only, and/or are ineffective for many people suffering from opioid addiction, and new therapies are desperately needed. One promising target is the brain galanin system; reducing galanin levels exacerbates morphine reward and withdrawal, while increasing galanin opposes opioid addiction-like behaviors. However, the neuroanatomical source and target of this protective galanin have not been identified, and the effects of galanin on voluntary opioid intake have not been investigated. The locus coeruleus (LC) modulates the activity of the mesolimbic reward pathway and has been implicated in opioid addiction, and 80% of noradrenergic neurons in this nucleus co-express galanin. We have assembled a set of genetically altered mice that either lack or overexpress galanin specifically in noradrenergic neurons to test the hypothesis that LC-derived galanin suppresses the ability of opioids to disinhibit dopamine (DA) neurons in the ventral tegmental area (VTA) and attenuates opioid reward/reinforcement, as well as acts in an autocrine manner to prevent LC hyperactivity and reduces withdrawal symptoms. In Aim 1, we will use in situ hybridization to determine the neurochemical identity of galanin receptor-expressing cells in the VTA, and slice and in vivo electrophysiology to investigate the circuitry and cellular mechanisms underlying the ability of galanin to oppose opioid-induced VTA DA neuron activity. In Aim 2, we will use the transgenic mice described above to test the hypothesis that LC-derived galanin inhibits opioid reinforcement using an operant i.v. opioid self- administration paradigm. In Aim 3, we will assess the ability of galanin to suppress LC hyperactivity, cellular plasticity, and aversive symptoms during opioid withdrawal. Completion of these aims will lay the groundwork for LC/galanin-based therapies for opioid addiction.
项目摘要 阿片类药物流行已被宣布为国家公共卫生紧急状态。目前的治疗方法有滥用 易感性,仅针对急性过量,和/或对许多阿片成瘾患者无效,以及 迫切需要新的治疗方法。一个有希望的目标是大脑甘丙素系统;减少甘丙素 水平加剧了吗啡的奖赏和戒断,而增加甘丙素则反对阿片类成瘾 行为。然而,这种保护性甘丙素的神经解剖学来源和靶点尚未确定, 甘丙肽对阿片类药物自愿摄取的影响尚未被调查。蓝斑(LC) 调节中脑边缘奖赏通路的活性,并与阿片成瘾有关,以及 该核团中80%的去甲肾上腺素能神经元共表达甘丙素。我们已经组装了一套基因上的 改变缺乏或过度表达去甲肾上腺素能神经元甘丙素的小鼠来验证这一假说 LC来源的甘丙素抑制阿片类药物抑制腹侧多巴胺(DA)神经元的能力 被盖区(VTA)和减弱阿片类药物奖励/强化,以及以自分泌方式作用于 预防LC多动,减少戒断症状。在目标1中,我们将使用原位杂交来 测定VTA、切片和体内甘丙肽受体表达细胞的神经化学特性 电生理学:研究甘丙素的电路和细胞机制。 对抗阿片类药物诱导的VTA DA神经元活动。在目标2中,我们将使用上述转基因小鼠 使用操作剂静脉注射来测试LC衍生的甘丙素抑制阿片类药物强化的假设。阿片类自我 管理范式。在目标3中,我们将评估甘丙肽抑制LC细胞过度活动的能力。 阿片类药物戒断时的可塑性和厌恶症状。这些目标的实现将奠定基础 以LC/Galanin为基础的阿片成瘾治疗。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID WEINSHENKER其他文献

DAVID WEINSHENKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID WEINSHENKER', 18)}}的其他基金

Contribution of neuromelanin to selective vulnerability of locus coeruleus neurons in Alzheimer's disease
神经黑色素对阿尔茨海默氏病蓝斑神经元选择性脆弱性的贡献
  • 批准号:
    10525513
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
Contribution of locus coeruleus-derived galanin to opioid reward and reinforcement
蓝斑源甘丙肽对阿片类药物奖励和强化的贡献
  • 批准号:
    9981143
  • 财政年份:
    2020
  • 资助金额:
    $ 46.38万
  • 项目类别:
Contribution of locus coeruleus-derived galanin to opioid reward and reinforcement
蓝斑源甘丙肽对阿片类药物奖励和强化的贡献
  • 批准号:
    10456900
  • 财政年份:
    2020
  • 资助金额:
    $ 46.38万
  • 项目类别:
Emory Alzheimer's Disease Research Center
埃默里阿尔茨海默病研究中心
  • 批准号:
    10408030
  • 财政年份:
    2020
  • 资助金额:
    $ 46.38万
  • 项目类别:
Emory Alzheimer's Disease Research Center
埃默里阿尔茨海默病研究中心
  • 批准号:
    10212237
  • 财政年份:
    2020
  • 资助金额:
    $ 46.38万
  • 项目类别:
Emory Alzheimer's Disease Research Center
埃默里阿尔茨海默病研究中心
  • 批准号:
    10673961
  • 财政年份:
    2020
  • 资助金额:
    $ 46.38万
  • 项目类别:
Contribution of locus coeruleus-derived galanin to opioid reward and reinforcement
蓝斑源甘丙肽对阿片类药物奖励和强化的贡献
  • 批准号:
    10268173
  • 财政年份:
    2020
  • 资助金额:
    $ 46.38万
  • 项目类别:
2017 Catecholamines Gordon Research Conference & Gordon Research Seminar
2017年儿茶酚胺戈登研究会议
  • 批准号:
    9321523
  • 财政年份:
    2017
  • 资助金额:
    $ 46.38万
  • 项目类别:
Neurobiology of Reward Choice
奖励选择的神经生物学
  • 批准号:
    9304986
  • 财政年份:
    2016
  • 资助金额:
    $ 46.38万
  • 项目类别:
Neurobiology of Reward Choice
奖励选择的神经生物学
  • 批准号:
    9181667
  • 财政年份:
    2016
  • 资助金额:
    $ 46.38万
  • 项目类别:

相似海外基金

Structural basis for regulation of beta2 adrenergic receptor signaling by the dynamic post-translational modification S-palmitoylation
动态翻译后修饰S-棕榈酰化调节β2肾上腺素受体信号传导的结构基础
  • 批准号:
    10603466
  • 财政年份:
    2023
  • 资助金额:
    $ 46.38万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
    Discovery Grants Program - Individual
Glucocorticoid and Adrenergic Receptor Signaling at the Neuroimmune Interface
神经免疫界面的糖皮质激素和肾上腺素能受体信号传导
  • 批准号:
    RGPIN-2019-04706
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
    University Undergraduate Student Research Awards
Angiotensin-(1-7) and beta adrenergic receptor signaling in aging
衰老过程中血管紧张素 (1-7) 和 β 肾上腺素受体信号传导
  • 批准号:
    10448574
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
Angiotensin-(1-7) and beta adrenergic receptor signaling in aging
衰老过程中血管紧张素 (1-7) 和 β 肾上腺素受体信号传导
  • 批准号:
    10629280
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase
磷酸肌醇 3-激酶对 β-肾上腺素能受体功能的新调节
  • 批准号:
    10591688
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
    University Undergraduate Student Research Awards
The molecular mechanism of the crosstalk between the beta-2 adrenergic receptor and chemokine receptors in lymphocytes
淋巴细胞β2肾上腺素受体与趋化因子受体串扰的分子机制
  • 批准号:
    22K07118
  • 财政年份:
    2022
  • 资助金额:
    $ 46.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了